Turn £10k Into £30k With AstraZeneca plc

AstraZeneca plc (LON: AZN) would have trebled your money in 10 years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaIf you’d held AstraZeneca (LSE: AZN) (NYSE: AZN.US) shares over the past 12 months, you’d have done pretty nicely with a 40% rise to 4,544p.

A lot of that is down to the Pfizer bid, mind, but the turnaround plan put in place by new boss Pascal Soriot was already boosting the shares. And over three years you’d be sitting on a gain of more than 60%.

But Fools are in it for the long term, so what would an investment in AstraZeneca a full 10 years ago be worth now?

Double your money

In September 2004, AstraZeneca shares were changing hands for around 2,265p, so if you’d invested £10,000 at the time you would have picked up 442 shares. Wind forward to today, and with AstraZeneca shares priced at 4,544p you’d have enjoyed a 101% capital gain — you’d have more than doubled your £10,000 in 10 years to £20,062.

Bear in mind that the period covered two traumatic events for AstraZeneca. One was the recession that hit the entire FTSE, but we also had the so-called patent cliff that saw the end of protection of some key drugs. Between late 2006 and early 2008, AstraZeneca shares lost a massive 49%, and investors could be forgiven for not being too impressed by the stock market at the time.

But even if you’d bought in at the very peak of 2006 and suffered the crunch, your shares would still be worth 30% more today! As failures go, I’ve seen worse.

Don’t forget the dividends

If that 10-year doubling impressed you, don’t forget there’s more to come in the shape of dividends. Early in the decade, AstraZeneca was handing out yields of between 2% and 3%, which was a little below the FTSE 100 average. But the dividend was on the rise, and by 2009 it was yielding 5% — and it got as high as 6.1% in 2011.

Altogether, the annual cash handout would have netted you an additional £5,617, giving you a total of £25,679 for an overall return of 157%.

But we don’t want to give you that!

Buy more shares!

No, if you hadn’t needed to spend your dividends, you’d have built an even bigger pot had you reinvested the cash in more AstraZeneca shares every year.

Just those few extra few shares every year would have added another £4,471 to your investment! That’s an extra 45% return on your original £10,000.

Your total gain with all dividends reinvested over 10 years? A pretty cool £30,150! And you’d be starting the next decade with 639 shares instead of your original 442.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black woman at home texting on her cell phone while sitting on the couch
Investing For Beginners

Experts think this penny stock could rise by 80% or more in the coming year

Jon Smith points out a penny stock that has the potential to soar this year if international expansion pays off,…

Read more »

Investing Articles

What next for Barclays shares, after this shock 15% slump?

What a tangled web we encounter when we look too deeply into the workings of the global banking sector. Barclays…

Read more »

Hydrogen testing at DLR Cologne
Investing Articles

Will the Rolls-Royce share price rise 5% or 36% by this time next year?

Rolls-Royce's share price hit new heights after stunning full-year results on Thursday (26 February). Can the FTSE 100 firm keep…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Airtel Africa’s shares are up as others on the FTSE 100 plummet. What’s going on?

With yet another conflict starting in the Middle East, James Beard notes that investors are still buying Airtel Africa’s shares.…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Hot dates for dividend investors to mark in their March diaries

The year's stock market gains might be taking some edge off high yields, but UK dividend investors still have plenty…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

Is it time to snap up Nvidia stock, after it fell 9% on Q4 results?

Nvidia makes a laughing stock of naysayers and their doom-and-gloom moods yet again, but the stock responds with a hefty…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

How much do you need in an ISA to generate a second income of £2,700 a month in 2050?

Ben McPoland highlights a 6%-yielding stock from the FTSE 100 index that could contribute towards an attractive second income.

Read more »

Iberian plane on runway
Investing Articles

Is this a once-in-a-decade chance to snap up my highest conviction UK share?

Harvey Jones is a big fan of this beaten-down UK share and reckons it offers some of the most exciting…

Read more »